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The adequate timing of adjuvant radiotherapy (RT) in breast cancer has become a subject of increasing interest in recent years. A
population-based study was undertaken to determine the influence of demographic and clinical factors on the postoperative RT delay
in patients treated with breast-conserving surgery (BCS) and to assess the impact of delay on survival. In total, 7800 breast cancer
patients treated with BCS and adjuvant RT between 1986 and 1998 in Yorkshire were included in the study. The median interval
between surgery and the start of RT (S–RT interval) was 8 weeks (7 weeks for chemotherapy negative and 11 for chemotherapy
positive patients). This interval increased substantially over time from 5 weeks during 1986–1988, irrespective of patients’
chemotherapy status, to 10 and 17 weeks among chemotherapy negative and chemotherapy positive patients, respectively, in 1997–
1998. The S–RT interval was also significantly influenced by travel time to RT centre, year and at which RT centre patient had the
treatment (Po0.001). Overall, 5-year survival was 82%. Patients with S–RT intervals longer than 9 weeks had a trend towards an
increased relative risk of death. This reached a statistical significance at 20–26 weeks (RR 1.49, 95% CI (1.16–1.92)). The findings of
our study suggest that delaying the initiation of RT for 20–26 weeks after surgery is associated with decreased survival in patients
treated with conservation surgery.
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Breast irradiation is now accepted as standard adjuvant therapy
following breast-conserving surgery (BCS) (NICE, 2002). Evidence
from randomised clinical trials suggests that the use of radio-
therapy (RT) is associated with a significantly lower rate of local
recurrence in patients treated with BCS (EBCTCG, 2000).
Achieving local tumour control is important as relapse often leads
to removal of the breast and can result in uncontrolled local
disease (Rutqvist, 1996). A causal relationship between local
recurrence and distant metastasis has been suggested (Cowen et al,
2000), but the meta-analyses and individual clinical trials have so
far yielded conflicting results about the survival advantage due to
adjuvant RT (Van de Steene et al, 2000).
Although there is a common understanding that the effective-
ness of adjuvant therapy diminishes with increasing number of
clonogenic cancer cells and that such treatment should begin as
soon after surgery as is practical (Kurtz, 2002), the maximal safe
time interval between breast cancer surgery and the start of RT has
not yet been established. Long delays in beginning postoperative
RT have been linked to increased risk of local recurrence (Huang
et al, 2003) but very few studies have looked at the effect on
survival. Despite the scarce evidence, concerns about increasing
delays in start of RT experienced by breast cancer patients
prompted recommendations about the acceptable delays (JCCO,
1993; Clinical Guidelines, 1998; Rutgers, 2001).
We undertook this study in order to investigate the extent of
delay in the start of radiation therapy after BCS between 1986 and
1998 in Yorkshire. Our aim was to establish personal, tumour and
treatment factors that influenced the postoperative RT delay in
breast cancer patients, and examine any relationship between
delay and survival.
MATERIALS AND METHODS
Study population
All female breast cancer patients diagnosed in the former
Yorkshire Regional Health Authority area between 1 January
1986 and 31 December 1998 were identified from the Northern and
Yorkshire Cancer Registry and Information Service (NYCRIS)
database (n¼27941). Patients were excluded from the study if
they did not have surgery, had a mastectomy, did not receive RT or
had preoperative RT. Cases with known metastatic disease at the
time of diagnosis were also excluded from the study.
A case note review of a small sample of patients that had RT
later than 6 months after the surgery (n¼16) indicated that a
proportion of them received RT for local recurrence or for
palliative purposes. As the RT intent was not available in cancer
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lregistry data set for the study period, it was not possible to
determine patients who had RT for primary tumour without
reviewing case notes of all patients with RT delays longer than 6
months. These cases were, therefore, excluded from the analyses. A
review of a sample of 36 case notes of patients who received RT up
to 6 months postoperatively showed that the RT was a part of the
treatment for the primary tumour in all patients. The total number
of cases eligible for the study after all exclusions was 7800.
Patient, tumour and treatment details relevant to the study were
abstracted from the NYCRIS database. The pathological (TNM)
stage of disease was known for 3781 (48.5%) cases. Based on the
information available, an additional 2647 (33.9%) cases were
staged: stage I/II (n¼2126) if cancers were less than 2cm in size
and information about the nodal status was not available, and II/III
(n¼521) if size was 45cm and lymph nodes were either positive
or unknown. For 1372 cases (18%) information available on the
NYCRIS database was not sufficient to allow for stage classifica-
tion; these were included in the analyses as a group of ‘stage
unknown’. The Carstairs deprivation index (Carstairs and Morris,
1989) was used as a proxy for socioeconomic status and was
determined by the postcode of patients’ residence. Estimated car
travel time to RT centre was calculated using a Geographical
Information System (GIS). These estimates were based on the
location of patients and RT centres postcodes, a digital version of
the road network, and information on average vehicle speeds over
different road types.
Patients included in the study received radiation treatment in
one of four RT centres: Leeds (n¼5290), Hull (n¼1697), Lincoln
(n¼511) and Middlesborough (n¼302). Although RT centres in
Lincoln and Middlesborough were not within the former Yorkshire
Region area, because a considerable number of Yorkshire patients
received their RT treatment in these two centres, they were
included in all analyses (descriptive and survival) apart from the
multivariate analyses of factors associated with the RT delay as
they only represented a portion of their case load. These patients
were Yorkshire residents and, therefore, may not be representative
of the overall population of patients seen at these hospitals.
Furthermore, while some of these patients were residing near the
border of the region others may have had different reasons why
they were referred or chose to go for RT outside Yorkshire and,
therefore, results of analyses of the factors associated with the RT
delay may be have been biased by including this group of patients.
All patients were divided into six groups according to interval
between the date of their surgery (date of first surgery in cases
when patients had more than one operation) and the date of start
of radiation treatment (1–4 weeks, 5–6, 7–8, 9–12, 13–19 and
20–26 weeks). Separate descriptive analyses were undertaken for
patients who received adjuvant CT (CTþ group) and for cases
where adjuvant CT was not administered (CT  group).
Data analysis
Factors associated with the RT delay The influence of the
following variables was investigated in relation to the interval
between surgery and the start of RT (S–RT interval): age, tumour
stage, year of diagnosis, CT, hormone therapy, NHS hospital Trust,
RT centre, travel time to RT centre, Carstairs index and whether
patient had a second surgical procedure.
After univariate analyses, multivariate linear regression analyses
were performed by fitting a model with all variables and all two-
factor interactions. Terms were then removed from the model by
backward elimination with a threshold for inclusion of a P-value of
0.01. The nonsignificant main effect terms were kept in the model
if they had a statistically significant interaction with another
variable.
Survival analysis The overall 5-year survival for each S–RT
category was estimated using the Kaplan–Meier method (Kaplan
and Meier, 1958). The survival period for each patient was
calculated as the time difference between the date of diagnosis and
the death date or censoring date (1 December 2001). Multivariate
analysis was performed using the proportional hazards regression
model (Cox, 1972). Estimates of the relative risk of death were
initially considered for each factor (age, stage, grade, deprivation
index, time period, travel time and whether chemotherapy and/or
hormone therapy was received) in isolation, and then in a
multivariate model using a stepwise approach where each factor
was introduced. In the end, only factors that had an impact on the
relative risk of dying were left in the model and the relative risks
were adjusted for the variation in all those factors.
RESULTS
The total number of breast cancer patients included in this study
was 7800. One-third of the study population (32.4%) were younger
than 50 years at the time of diagnosis while 13% were older than 70
years (Table 1). The median age at diagnosis was 55 years. A large
proportion of patients (74.9%) had either stage I or stage II disease
(I, I/II or II). A quarter of all cases received CT (n¼1857, 23.8%)
and 82% (n¼6384) received hormone therapy (Tamoxifen). More
than 70% of patients lived within 30min estimated travel time
from the RT centre where they received their treatment (mean
travel time was 23min).
Table 1 Female breast cancer patients resident in former Yorkshire
Regional Health Authority area, treated with breast-conserving surgery and
adjuvant radiotherapy, diagnosed 1986–1998 by age, stage and time
period of diagnosis, treatment with chemotherapy and hormone therapy
and travel time from home to radiotherapy treatment centre
No. of patients % of patients
Age (years)
o40 755 9.7
40–49 1768 22.7
50–59 2353 30.2
60–69 1931 24.8
70+ 993 12.7
Stage
I 699 9.0
I/II 2126 27.3
II 3009 38.6
II/III 521 6.7
III 73 0.9
N/K 1372 17.6
Chemotherapy
Positive 1857 23.8
Negative 5943 76.2
Hormone therapy
Positive 6384 81.8
Negative 1416 18.2
Travel time
1–14min 2224 28.5
15–29min 3368 43.2
30+ min 2129 27.3
N/K 79 1.0
Time period at diagnosis
1986–1988 1308 16.8
1989–1990 903 11.6
1991–1992 1204 15.4
1993–1994 1387 17.8
1995–1996 1404 18.0
1997–1998 1594 20.4
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and the start of RT was 7.6 weeks (53 days, range 8–182 days); 7
weeks (49 days) in the CT  group and 11 weeks (77 days) in the
CTþ group (Table 2). In the first 4 weeks after surgery, 1013 or
13.0% (n¼814 or 13.7% in CT  group) of patients started their
RT treatment.
The S–RT interval increased steadily over the study period. In
the earliest time period (1986–1988), the average S–RT interval
was about 5 weeks irrespective of patients’ CT status (Table 3). By
1997–1998, this has increased to 10 weeks among CT  patients
(71 days) and 17 weeks in CTþ patients (120 days). The
proportion of CT  patients who started their RT during the first
4 weeks was 40% in 1986–1988 in contrast to only 1% in 1997–
1998. While only three patients waited 20–26 weeks for the start of
their RT between 1986 and 1988, 199 cases (12.5%) waited the
same amount of time during 1997–1998.
There was a wide variation between NHS Hospital Trusts in how
soon patients started radiation treatment (Figure 1). For example,
CT  patients from three hospitals that referred all their patients to
the same RT centre for treatment, had significantly different mean
S–RT intervals of 55, 62 and 76 days. Whether patients lived in
deprived or affluent areas made little difference to their S–RT
intervals if they did not receive adjuvant CT (Figure 2). However,
CTþ patients who lived in more affluent areas had significantly
shorter intervals than those who lived in the most deprived areas,
77 days (95% CI 73.36–81.34) and 93 days (95% CI 88.83–97.57)
respectively. Travel time to RT centre also made little difference to
S–RT intervals in the CT  group but had a significant impact
among patients who had CT (Figure 3). CTþ patients who had to
travel longer distances for RT, started their RT sooner than those
who lived nearer to the RT centre. Patients who lived within 15min
from their RT centre had on average 4 weeks longer S–RT
intervals than those who had to travel more than 30min (97 and 69
days, respectively).
The results of multivariate analyses of patients’ and treatment
factors influence on the S–RT interval are presented in Table 4.
The year of diagnosis, whether patient received CT, tumour stage,
RT centre where treatment was received and travel time to RT
centre, all had a statistically significant influence on the S–RT
interval (Po0.001). Significantly shorter S–RT intervals were seen
for patients who did not receive CT, those diagnosed in earlier time
periods and those living further from the RT centre. Age and
Carstairs index were statistically significant in univariate analyses
but not in multivariate analysis after the adjustments were made
for variation of all other factors. The following interactions had a
significant effect on the S–RT interval: year of diagnosis and
Table 2 Study patients by time interval between surgery and radio-
therapy (S–RT interval) and whether or not chemotherapy (CT) received
S–RT interval
(weeks)
CT+ no. of
patients (%)
CT  no.
of patients (%)
All no. of
patients (%)
1–4 199 (10.7) 814 (13.7) 1013 (13.0)
5–6 268 (14.4) 1438 (24.2) 1706 (21.9)
7–8 210 (11.3) 1369 (23.0) 1579 (20.2)
9–12 331 (17.8) 1681 (28.3) 2012 (25.8)
13–19 501 (27.0) 579 (9.7) 1080 (13.8)
20–26 348 (18.7) 62 (1.0) 410 (5.3)
All 1857 5943 7800
Median S–RT (days) 77 49 53
Table 3 Mean time interval between surgery and radiotherapy by time period and whether or not chemotherapy (CT) received
CT+ CT  All RT patients
Time period
Mean no. of
days (95% CI)
No. of
patients
Mean no. of
days (95% CI)
No. of
patients
Mean no. of
days (95% CI)
No. of
patients
1986–88 31.6 (29.8–33.5) 204 36.5 (35.4–37.6) 1104 35.7 (34.8–36.7) 1308
1989–90 42.9 (38.9–46.9) 141 43.2 (41.5–44.9) 762 43.2 (41.6–44.7) 903
1991–92 60.7 (56.1–65.3) 251 50.9 (49.3–52.4) 953 52.9 (51.4–54.4) 1204
1993–94 87.3 (83.2–91.4) 400 57.8 (56.5–59.2) 987 66.3 (64.7–68.0) 1387
1995–96 97.7 (93.9–101.5) 431 61.1 (59.7–62.5) 973 72.3 (70.6–74.1) 1404
1997–98 120.2 (116.8–123.6) 430 70.7 (69.3–72.1) 1164 84.0 (82.3–85.8) 1594
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Figure 1 Mean time interval between surgery and radiotherapy by
Hospital Trust (chemotherapy negative patients only). 1–10 referred
mainly to RT centre A; 11 – private patients; 12–13 referred to either RT
centre A or RT centre B; 14–18 referred mainly to RT centre B.
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Figure 2 Mean time interval between surgery and radiotherapy by
deprivation category and chemotherapy (CT) status.
Postoperative radiotherapy delay in breast cancer and survival
JS Mikeljevic et al
1345
British Journal of Cancer (2004) 90(7), 1343–1348 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lwhether patient received CT, CT and travel time, CT and RT centre
and CT and travel time. The statistically significant interaction
between time period and travel time showed that in later years
there was a trend towards shorter intervals for patients that had
longer journeys to RT centre.
The overall 5-year survival was 82.1%. Five year survival by S–
RT interval category is presented in Table 5. Women who started
RT within first 6 weeks from surgery had a 5-year survival of 80%
while it was 76% for patients with a RT delay of 20–26 weeks. The
multivariate analyses showed that survival was adversely affected
by longer delays (Table 5). After adjustments for the variation in
patients’ age, stage, grade, deprivation index, time period and
whether CT was received, there was a trend towards an increased
risk of death in S–RT interval categories longer than 9 weeks. A
statistically significant increase in the relative risk of death
occurred in patients that had their radiation treatment delayed
by 20–26 weeks after operation (RR 1.49, 95% CI 1.16–1.92).
DISCUSSION
This retrospective analysis of a large population-based cohort of
breast cancer patients in Yorkshire who received BCS and RT
suggests that the timing of adjuvant RT in breast cancer may be
important. Patients who commenced RT treatment between 20 and
26 weeks after surgery had an increased relative risk of death (RR
1.49, 95% CI (1.16–1.92)). These patients had a similar stage
distribution but were generally younger than the rest of study
population and had a considerably higher CT rate (84.9%).
Although only 5% of all patients included in the study started
their radiation treatment 20–26 weeks postoperatively, the
proportion increased steadily from less than 1% during 1986–
1988 to 13% of all patients diagnosed in 1997 and 1998. The trend
of increasing delay and the association between RT delay and
poorer survival was observed irrespective of the use of adjuvant
chemotherapy and persisted after adjustment for stage and age.
Although there is a considerable interest in whether the
increasing delays experienced by breast cancer patients before
receiving adjuvant RT have adverse effects on outcomes, only a
limited number of studies have examined this issue. These have
mainly focused on the association with local recurrence, and there
are very few published studies of survival. In a small study of 46
breast cancer patients in the US treated with BCS, poorer survival
was associated with delays longer than 7 weeks in CT  patients
while no significant effects on survival were found in CTþ
patients when their radiation treatment was initiated more than 24
weeks postoperatively (Ampil et al, 1999). In another US study,
breast cancer patients who received RT within 6 months after
surgery were compared with patients who had RT postponed for
longer than 6 months, and a significantly poorer survival in the
latter group was found (Buchholz et al, 1993). Both groups of
patients had BCS and CT. In contrast to these two studies, in the
IBSCG trial, no significant differences were found in the disease-
free survival between a 4- or 7-month RT delay period in
premenopausal node-positive CTþ women or between a 2- or
4-month period of delay in postmenopausal patients (Wallgren
et al, 1996). Similarly, no difference in survival was found in CT 
patients who had RT delayed for more than 16 weeks after BCS in a
Canadian study (Vujovic et al, 1998). Huang et al reviewed
available published studies in this area of studies and their analysis
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Figure 3 Mean time interval between surgery and radiotherapy by travel
time from home to radiotherapy treatment centre and chemotherapy (CT)
status.
Table 4 Multivariate analysis of demographic, pathologic and treatment
factors associated with the time interval between surgery and radiotherapy
(S–RT interval)
Factor
Adjusted S–RT
interval (days)
a
95% Confidence
interval
Chemotherapy
No 45.6 44.2–46.9
Yes 57.7 55.2–60.3
Stage
I 52.5 50.5–54.7
I/II 48.8 50.8–53.2
II 52.0 42.9–58.3
II/III 54.5 52.0–57.0
III 50.0 47.2–50.3
Time period at diagnosis
1986–1988 31.2 29.8–32.7
1989–1990 37.8 35.9–39.8
1991–1992 45.5 43.5–47.6
1993–1994 61.2 58.7–63.8
1995–1996 66.4 63.8–69.2
1997–1998 83.3 80.0–86.8
Travel time (min)
o15 53.2 51.2–55.2
15–22 53.0 50.8–55.2
23–29 51.5 49.3–53.7
30+ 47.7 46.0–49.5
RT centre
A 55.3 54.2–56.5
B 47.6 44.8–50.5
aAdjusted for CT, stage, time period, RT centre, Carstairs category and travel time.
Table 5 Five-year survival and relative risk of death (95% confidence
interval)
S-RT interval
(weeks)
5-year
survival Unadjusted RR Adjusted
a RR
1–4 80.1% (78.5–83.4) 1.00 1.00
5–6 80.1% (78.1–82.0) 0.95 (0.84–1.09) 1.04 (0.91–1.19)
7–8 84.4% (82.6–86.3) 0.81 (0.70–0.93) 0.99 (0.85–1.15)
9–12 84.3% (82.6–86.0) 0.80 (0.70–0.92) 1.04 (0.89–1.22)
13–19 81.0% (78.6–83.6) 0.92 (0.78–1.09) 1.16 (0.96–1.40)
20–26 75.7% (71.1–80.3) 1.25 (1.00–1.55) 1.49 (1.16–1.92)
aAdjusted for age, stage, grade, deprivation index, time period and whether
chemotherapy was received (all continuous variables were categorised before
analyses; categories were same as presented in Table 1). Tested also for travel time
and whether hormone therapy was received, but were dropped from the final
analysis as they did not have significant effect on relative risks of death.
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probability (Huang et al, 2003). Guidelines (JCCO, 1993; Clinical
Guidelines, 1998; Rutgers, 2001) concerning the timing of adjuvant
radiation therapy in breast cancer patients treated with BCS are
based on expert advice rather than research evidence.
The effect of treatment delays on outcomes cannot easily be
investigated in randomised controlled trials. Observational studies
based on high quality routinely recorded data are available for
exploring the relationship between therapeutic delay and survival.
In this retrospective population-based study, we included breast
cancer patients diagnosed within a population of over 3.6 million
who had BCS and adjuvant RT, and estimated the relative risk of
dying in relation to S–RT interval after adjusting for available
patient and clinical factors. The large sample size enabled
precision in the estimation of the association between RT delay
and survival. While there are limitations of cancer registry data,
including incompleteness of tumour stage information and a lack
of comorbidity and recurrence information, it is unlikely that they
could have biased this large population sample in relation to RT
delay. For the 18% of all patients without known stage of disease to
bias the survival estimates and be responsible for the effect of
decreased survival with long RT delays found in this study, it
would require a high proportion of them to be advanced cases who
had their RT systematically delayed. However, only a very small
proportion (5%) of patients with long S–RT intervals (20–26
weeks) did not have details about their tumour stage. Although
comorbidity information was not available, since patients in 20–26
weeks category were generally younger (median 48 years) in
comparison to rest of the study population, it is unlikely that
comorbidity could explain their poorer survival. Towards the end
of the study period new anthracycline-based CT regimens were
coming into routine practice that, in contrast to CMF (the previous
standard regimen containing cyclophosphamide, methotrexate and
5-fluorouracil), cannot be given concurrently with RT due to
increased toxicity. As the new regimens are usually given before
RT, there is a possibility that some CTþ patients with the long S–
RT intervals in our study population were given anthracycline-
based CT regimes. If they were also initially used selectively in
patients with poorer prognosis, this would indicate that patients
with long RT delays that received CT had worse prognoses than the
rest of the study population. Similarly, as patients in the 20–26
weeks interval category were generally younger than patients in
other S–RT categories, this might also be an indication of poorer
prognoses (as young age is known to be a prognostic factor
associated with worse outcomes). In the multivariate survival
analyses, we did, however, fully adjust the hazard ratios for
variation in age as well as variation in stage, a factor that was
known for 82% of all patients (95% of all patients in 20–26 weeks
category). Furthermore, patients with more advanced stage of the
disease did not have longer S–RT intervals than those with early
stages (Table 4). Although information about the type of CT
regimens used in CTþ patients was not available, our under-
standing is that the gradual change to anthracycline-based CT
began around 1995/1996 in Leeds, one of the two cancer centres in
the region. Since CMF was still the recommended treatment in the
national breast cancer guidance published in 1996 (Cancer
Guidance, 1996) it is likely that the anthracycline-based CT was
not given to patients in the regional district hospitals until later,
possibly even after the end of our study period (1998). It was not
logistically feasible to review the case notes of nearly 1900 patients
diagnosed in 17 regional hospitals in order to determine details of
the CT regimens. The consistent trend of increased risk of death in
S–RT interval categories longer than 9 weeks would support a
more direct link between RT delay and survival, rather than a
factor that has not been adjusted for within the study population.
The effectiveness of postoperative RT in preventing or delaying
local recurrence in patients who undergo BCS is well established by
randomised controlled trials (Liljegren et al, 1999; EBCTCG, 2000;
Fisher et al, 2002). However, meta-analyses and individual clinical
trials have produced conflicting results about the survival
advantage due to adjuvant RT (Liljegren et al, 1999; EBCTCG,
2000; Van de Steene et al, 2000; Fisher et al, 2002). In the EBCTCG
meta-analysis, only a small (nonsignificant) survival benefit was
seen in patients randomised to receive RT and BCS compared to
those only treated surgically probably because the moderate
improvement in breast cancer mortality was counterbalanced by
an adverse effect on mortality from cardiovascular causes
(EBCTCG, 2000). It may appear that the association between
longer delays (20–26 weeks) in the start of RT and inferior survival
found in our study contradicts the EBCTCG results since the
negative survival impact of delayed RT is of greater magnitude
than the negative impact of no RT within the EBCTCG analysis.
The findings of this meta-analysis were however strongly
influenced by older trials when now redundant RT techniques
were used and the risk–benefit relationship may be substantially
more favourable with more modern RT practice. A worsening of
survival for a small group of patients whose RT is delayed is not
incompatible with the conclusions derived from meta-analyses of
randomised trials.
Breast cancer patients in Yorkshire experienced increasing
delays in the start of adjuvant RT since mid-1980s and delays in
the initiation of breast irradiation reported in this study are
considerably longer than the current national recommendations.
The trend of steadily increasing waiting times for RT following
surgery between 1986 and 1998 found in Yorkshire almost
certainly reflects the pattern present in RT departments through-
out the UK. A small survey of the postoperative RT waiting times
for operable breast cancer in the UK indicated that, in 1998, 39% of
women with no elective delay waited for adjuvant irradiation more
than the maximum target of 4 weeks (RCR, 1998). The greater use
of BCS and an increase in referral for RT in addition to inadequate
levels of equipment and staff resulted in a steady increase in
waiting times for RT across the country. However, due to the
significant differences in staffing, beds and equipment levels in RT
units within the UK (Department of Health, 1999), the problem is
more acute in some regions than in others (RCR, 1998). A survey
of RT services in the UK carried out in 2002 indicated that in spite
of 5 year national investments in both machines and staff, the RT
provision was not sufficient to keep up with the increasing demand
for RT (RCR, 2003). During 1997–2002, an increasing number of
machines used for planning and delivery of RT were out-of-date
and inadequate for the delivery of modern RT and there was still a
shortage of suitably trained oncologists, radiographers and
physicists, resulting in further increases in RT waiting times.
Increasing RT waiting times have also been reported in other
countries with similar health care systems (Mackillop et al, 1995).
Overall survival has increased over time despite increasing RT
delays. Since patients who had RT delayed for more than 20 weeks
after surgery represent a small proportion of all patients (5%,
n¼410), their excess risk of dying was not high enough to affect
overall survival. The excess risk associated with delayed RT is
relative to those that started RT within first 4 weeks, while the
trend in overall survival is based on an absolute measure. Survival
improved over time among all S–RT interval groups, but patients
in the group with longest S–RT delays (20–26 weeks) still had
poorer survival.
Radiotherapy treatment for breast cancer involves visits to a RT
centre for several days each week over several consecutive weeks.
The increased inconvenience of daily travelling to a RT centre for
patients who have long journeys can influence to a certain extent
the type of surgery they receive, but there is no evidence that it has
an effect on RT uptake (Cosford et al, 1997; Nattinger et al, 2001).
Our data suggest that the travel time or distance from RT centre
had an influence on how long patients’ RT treatment was delayed,
with shorter S–RT intervals among CTþ patients who lived
further from the RT centre. As mentioned earlier, during the study
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contrast to previous regimens, could not be given concurrently
with RT due to increased toxicity. It is possible that patients who
lived nearer to cancer centres were managed by specialist teams,
including medical oncologists, who adopted the new type of CT
regimens earlier than oncologists in other hospitals some distance
from cancer centres.
Wide variation of RT uptake between regional NHS Trusts, not
explained by the type of surgery performed, has been previously
reported (Sainsbury et al, 1995). Our findings suggest that a
significant variation exists between referring hospitals in how soon
patients begin RT. For example, the median S–RT interval in CT 
patients in one Trust was 35 days while it was twice as long (70
days) in another Trust. A delay in referral after surgery was
previously reported to be the most common reason for delays in
patients with S–RT intervals longer than 12 weeks (Vujovic et al,
1998). The period under study was before breast cancer multi-
disciplinary teams were formed and fully operational in most
Trusts. With the Breast Cancer Guidance published in 1996 (NHS
Executive, 1996), formation of multidisciplinary teams and
establishment of their local guidelines for referral and treat-
ment, there is a reason to hope that more equity of access now
exists.
Postoperative RT delays have been steadily increasing since
mid-1980s in the UK and other countries. It is therefore important
to have some understanding of the relationship between post-
operative RT delay and adverse treatment outcomes. There is now
good evidence that delayed RT increases the risk of local
recurrence (Huang et al, 2003). Our findings suggest that adjuvant
RT in BCS patients should not be unnecessarily delayed and
certainly should not commence later than 20 weeks following
surgery. Long delays are undoubtedly distressing for patients,
increase the risk of local recurrence and may have an adverse
impact on survival.
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